Dermatology

A woman scratching her skin
#Antibodies #Atopic dermatitis #Dermatology #Immunotherapy #Monoclonal antibodies

New dermatitis treatment shows promising long-term results

A novel, patient-tailored monoclonal antibody therapy has shown promise in treating moderate to severe atopic dermatitis.  Patients who participated in a clinical trial of rocatinlimab showed positive results while taking the drug and up to 20 weeks after stopping therapy, Mount Sinai researchers have… Read More

#News #Trending News

Alopecia
#Alopecia #Dermatology #Hair loss #JAK inhibitor #MHRA

First oral therapy for severe alopecia areata approved in UK

The MHRA has granted marketing authorisation for Eli Lilly’s baricitinib (Olumiant), the first licensed JAK inhibitor for the treatment of severe alopecia areata in adult patients.   The authorisation was based on BRAVE-AA1 and BRAVE-AA2 studies which both met the primary endpoint of the proportion of patients… Read More

#News #Regulatory

Child with eczema
#Atopic dermatitis #Biologics #Dermatology #Eczema #Monoclonal antibodies

First biologic therapy for young children with severe eczema

A biologic therapy for very young children with moderate to severe eczema (or atopic dermatitis) has been shown to be safe and effective in an international trial. Sponsored by Regeneron and Sanofi, the study of dupilumab in poorly controlled eczema is the first large-scale randomised double-blind trial of a monoclonal… Read More

#News

Plaque Psoriasis
#Dermatology #FDA #Plaque Psoriasis #Psoriasis

FDA approves new first-line therapy for plaque psoriasis

The US Food and Drug Administration (FDA) has approved Bristol Myers Squibb’s allosteric tyrosine kinase 2 inhibitor Sotyktu (deucravacitinib) for the treatment of adults with moderate-to-severe plaque psoriasis. It is approved in patients who are candidates for systemic therapy or phototherapy, but not recommended in combination with other potent immunosuppressants. Read More

#News